EGX-B

EGX-B
Clinical data
Other namesEGXB
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

EGX-B is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of December 2023, it is in the preclinical research stage of development.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.